Christine Stabell-Benn is a senior and experienced researcher with a long track record of vaccine research at the University of Southern Denmark. Her interest sets her apart from other vaccine researchers. She asks the question: a vaccine might protect from a specific disease that it is designed for – fine. But what is the TOTAL effect of the same vaccine on mortality from all causes? Will you live longer because of the vaccine? Or not? Normally one would consider this a valid and important question – if it weren’t for nationalistic vaccine politics and the huge financial interests that they incur. Let’s find our more (if we want to)…
Here’s her preprint paper in the Lancet (preliminary, not yet reviewed)
Christine’s idea is that vaccines can affect the immune system (and other bodily functions) in ways that are not specific to the virus it’s designed to protect against. Resulting in the vaccines either increasing or decreasing the lifespan of the vaccinated group, compared to placebo. These can be called “non-specific effects” and they can be good or bad.
In the particular example of the Covid vaccines, her recent research paper, which is a pre-print in the Lancet, suggests that the adenovirus vector vaccines may have a positive effect overall, versus placebo, in terms of helping people live longer.
Whereas the mRNA vaccines, versus placebo, may have a negative effect – largely because of cardiovascular inflammation side-effects such as myocarditis.
Specifically, more people died after having the mRNA vaccine than those who had the adenovirus vector vaccine.
The table below shows the data succinctly:
Note that the number of deaths here quite small overall, so it’s too early to jump to conclusions.
For example, we can see that the number of deaths in the mRNA vaccinated (31/37110) versus placebo (30/37083) is quite a small difference.
Christine goes on to make a couple of really good points:
- Specific to the Covid vaccines, we should have a head to head study of all-cause mortality (ie – how many people die after x amount of time) in both adenovirus vector vaccines versus mRNA vaccines. This would tell us if either of them are likely to increase or decrease mortality.
- Currently vaccines are approved based on their specific effectiveness to a specific viral target, and their short term safety profile. Whilst this sounds logical, once you accept that vaccines can have non-specific effects, it suggests that we should be looking at vaccines in terms of all-cause mortality over time
Since the pre-print has been published, Christine has responded to feedback on it here:
Here is a critically important table from the Lancet paper in which the adenovirus vector vaccines are the Johnson&Johnson and AstraZeneca ones, and the mRNA vaccines are those of Pfizer and Moderna:
If you have any experience in interpreting scientific papers, then the above Forest plot carries with it a clear message.
And it leads to a clear question as well:
Was all the Brexit-fuelled vitriol against the AstraZeneca vaccine, and the withdrawal of that vaccine in favour of the Pfizer-Moderna ones, really such a good idea? We will all have plenty of time to decide this for ourselves as this research continues, and if Christine Stabell-Benn’s tentative findings are subjected to further test.
Remember – it was similarly tentative findings from just a handful of cases that led to the blood clot story back in 2020 and the discrediting of the AstraZeneca vaccine.